Tokyo Tape
Sign in
← Alfresa Holdings

Half-year report · Q2

2784.TEDINET S100UPC8
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.46T2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥2.86T2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥1.43T2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥15.0bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥16.0bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥16.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥40.0bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥17.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥20.7bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥17.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥14.1bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥11.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥13.8bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥11.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.47Tat 2024-09-30Cons.Assets
Total assets¥1.45Tat 2024-03-31Cons.Assets
Total assets¥1.43Tat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥975.8bnat 2024-09-30Cons.Liabilities
Total liabilities¥967.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥491.3bnat 2024-09-30Cons.Net assets
Net assets / equity¥479.9bnat 2024-03-31Cons.Net assets
Net assets / equity¥465.6bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥206.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥213.8bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥204.6bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥212.3bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥184.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥158.8bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥2.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥86.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥63.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥8.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥14.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥8.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥7.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥19.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥29.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥75.262024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥154.132023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥60.292023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio33.5%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥18.0bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥18.0bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30¥174m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥1.30T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.29T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥9.6bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥12.7bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥27.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥18.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥8.1bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥188m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥18.4bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥18.4bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥248m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥132.4bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥132.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥258m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥1.47T
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥1.46T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥18.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥14.8bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥16.9bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥16.9bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥269m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.27T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.26T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥8.9bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥26.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥18.3bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥186m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥18.2bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥18.2bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥279m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥133.3bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥133.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥275m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.44T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.43T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥16.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥15.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 562
ItemContextValueUnit
Gross profitCurrentYTDDuration102310000000JPY
Selling general and administrative expensesPrior1YTDDuration83228000000JPY
Selling general and administrative expensesCurrentYTDDuration87315000000JPY
Operating incomePrior1YTDDuration15998000000JPY
Operating incomeCurrentYTDDuration14995000000JPY
Interest income noiPrior1YTDDuration29000000JPY
Interest income noiCurrentYTDDuration46000000JPY
Dividends income noiPrior1YTDDuration778000000JPY
Dividends income noiCurrentYTDDuration940000000JPY
Real estate rent noiPrior1YTDDuration270000000JPY
Real estate rent noiCurrentYTDDuration253000000JPY
Other noiPrior1YTDDuration484000000JPY
Other noiCurrentYTDDuration407000000JPY
Non operating incomePrior1YTDDuration1561000000JPY
Non operating incomeCurrentYTDDuration1647000000JPY
Interest expenses noePrior1YTDDuration35000000JPY
Interest expenses noeCurrentYTDDuration144000000JPY
Commission fee noePrior1YTDDuration69000000JPY
Commission fee noeCurrentYTDDuration0JPY
Rent expenses on real estates noePrior1YTDDuration89000000JPY
Rent expenses on real estates noeCurrentYTDDuration106000000JPY
Other noePrior1YTDDuration85000000JPY
Other noeCurrentYTDDuration112000000JPY
Non operating expensesPrior1YTDDuration280000000JPY
Non operating expensesCurrentYTDDuration363000000JPY
Ordinary incomePrior1YTDDuration17280000000JPY
Ordinary incomeCurrentYTDDuration16279000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration185000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration142000000JPY
Gain on sales of investment securities eiPrior1YTDDuration－JPY
Gain on sales of investment securities eiCurrentYTDDuration5428000000JPY
Subsidy eiPrior1YTDDuration－JPY
Subsidy eiCurrentYTDDuration743000000JPY
Extraordinary incomePrior1YTDDuration185000000JPY
Extraordinary incomeCurrentYTDDuration6314000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration19000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration4000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration74000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration32000000JPY
Impairment loss elPrior1YTDDuration4000000JPY
Impairment loss elCurrentYTDDuration48000000JPY
Loss on reduction of noncurrent assets elPrior1YTDDuration－JPY
Loss on reduction of noncurrent assets elCurrentYTDDuration743000000JPY
Loss on valuation of investment securities elPrior1YTDDuration11000000JPY
Loss on valuation of investment securities elCurrentYTDDuration20000000JPY
Loss on valuation of investments in capital elPrior1YTDDuration－JPY
Loss on valuation of investments in capital elCurrentYTDDuration142000000JPY
Loss on cancellation of leasehold contracts elPrior1YTDDuration－JPY
Loss on cancellation of leasehold contracts elCurrentYTDDuration94000000JPY
Cancellation penalty elPrior1YTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass